in this phase iii randomized study , 124 evaluable patients with unresectable non-small-cell lung cancer ( nsclc ) were randomized to vindesine v cisplatin ( 120 mg/m2 ) plus vindesine v cisplatin ( 60 mg/m2 ) plus vindesine plus mitomycin c .
C0280545
vindesine
C0042682
vindesine